Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group.
Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using a threshold greater than 15 degrees. That angle measures big-toe misalignment on an X-ray. Both figures matter because the definition determines which cases count as recurrence.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) also reported clinically meaningful improvements in patient-reported outcomes maintained through five years. The commercial question is whether this evidence can persuade more surgeons to adopt Lapiplasty and increase repeat use.
Bull Case
Five years of follow-up addresses an important concern in bunion surgery: whether correction lasts. For Treace Medical Concepts, Inc. (NASDAQ:TMCI), sustained alignment and patient-reported improvement provide a stronger foundation for surgeon education than early postoperative results alone.
ALIGN3D was a company-funded, prospective, multicenter study without a comparison group, involving seven U.S. sites and 13 surgeons. That gives the evidence breadth beyond one surgeon’s practice, although patient selection still matters when applying the findings elsewhere.
Lapiplasty combines instruments, implants, and a surgical technique designed to correct the deformity in three dimensions and stabilize the affected joint. Durable results could help Treace Medical Concepts, Inc. (NASDAQ:TMCI) explain the value of that approach to surgeons evaluating competing systems.
Existing surgeon relationships provide a commercial starting point. In the second quarter, approximately 40% of Lapiplasty surgeon users incorporated at least one of three newer bunion systems, up from 35% in the first quarter. That adoption predates the five-year announcement, but suggests opportunities to deepen usage across the broader portfolio.
Bear Case
The disclosed analysis does not establish superiority over competing procedures through a randomized comparison. Differences in patient characteristics, surgical technique, and recurrence definitions make comparisons with unrelated studies difficult.
Four-year follow-up and complication details have already been published. The final five-year analysis did not include 36 of the 173 treated patients. Their absence does not establish poor outcomes, but their results could affect the interpretation of durability. Reasons for missing follow-up and endpoint-specific patient counts in the final five-year dataset would help investors assess the evidence.
